Health Catalyst, Inc. (HCAT): Results of Operations and Financial Condition
Health Catalyst, Inc. (HCAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2ex991-earningspress.htm EX-99.1 Document Exhibit 99.1 Health Catalyst Reports Second Quarter 2026 Results SALT LAKE CITY, UT, August 6, 2026 — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measur
How this was made
The 30-second read
Why it matters
The key tradable inputs are the Q3 2026 revenue and Adjusted EBITDA guidance ranges, plus the completion of the Vitalware divestiture and full repayment of the credit facility debt, which together affect both near-term earnings expectations and balance-sheet risk.
Market read
Investors get a fresh guidance reset for Q3 2026 profitability (Adjusted EBITDA $0-$0.5M) alongside balance-sheet improvement from debt repayment, setting up a near-term sentiment and positioning shift.
What to watch
Traders may overweight the Q3 EBITDA range without separating GAAP net loss drivers from non-GAAP adjustments, and without assessing how the Vitalware divestiture affects future revenue mix and margins.
Background
This is an SEC 8-K with an earnings press release exhibit, including Q2 2026 results, forward guidance, and disclosures tied to a Vitalware divestiture and credit facility repayment.
Ticker impact
Health Catalyst reported Q2 results and guided Q3 2026 total revenue to $55M-$56M and Adjusted EBITDA to $0-$0.5M.
Near-term volatility risk is elevated into the Q3 setup, with traders likely to focus on whether the low Adjusted EBITDA range reflects seasonality or demand/margin pressure.
The article provides fresh, decision-relevant guidance ranges for Q3 and full-year 2026, and it discloses a completed divestiture and full credit facility repayment, both of which can re-rate risk and expectations.
Market effects
Healthcare analytics and health-system intelligence providers may see read-through on how investors price recurring revenue versus project-based profitability.
Limited direct regional spillover; primarily impacts US small/mid-cap healthcare software sentiment.
Low global relevance beyond US healthcare IT investor positioning.
Counterpoint
The $0-$0.5M Adjusted EBITDA range for Q3 could be temporary (timing of costs, revenue recognition, or transition effects) while the full-year Adjusted EBITDA range remains intact.
Key entities
- companyHealth Catalyst, Inc.
Nasdaq-listed healthcare intelligence company reporting Q2 2026 results and providing Q3 and full-year 2026 guidance.
- assetVitalware
Divested business unit whose sale is described as recently closed, with stated balance-sheet benefits.